



RLL-5.4DIV

S.B.
4-5-01

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

Applicant: Anand et al. Examiner: TBA
Application No.: 09/578,239 Group Art Unit: 1613
Filing Date: May 24, 2000
For: 1-(4-ARYLPIPERAZIN-1-YL)-OMEGA-[N-(ALPHA,OMEGA-DICARBOXIMIDO)]-ALKANES USEFUL AS URO-SELECTIVE ALPHA1-ADRENOCEPTOR BLOCKERS

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Box Issue Fee
Washington, DC 22031

In accordance with 37 CFR §§ 1.56 and 1.97, attached hereto is Form 1449 and copies of the references cited therein.

Authority is hereby given to charge any fees due in connection with this Information Disclosure Statement to Deposit Account No. 50-0912. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

ANAND *et al.*

By:

Jayadeep R. Deshmukh, Reg. No. 34,507

Dated: March 26, 2001
Ranbaxy Laboratories Limited
600 College Road East, Suite 2100
Princeton, New Jersey 08540
Tel: (609) 720-5608
Fax: (609) 720-9879

RECEIVED
MAR 30 2001
TECH CENTER 1600/2900

CERTIFICATE OF MAILING BY FIRST CLASS MAIL (37 CFR 1.8)

Applicant(s): ANAND ET AL.

Docket No.

RLL-5.4DIV

Serial No.

09/578,239

Filing Date

MAY 24, 2000

Examiner

TBA


Group Art Unit

1613

Invention:

1-(4-ARYLPIPERAZIN-1-YL)-OMEGA-[N-(ALPHA,OMEGA-DICARBOXIMIDO)]-ALKANES USEFUL AS

URO-SELECTIVE ALPHA 1-ADRENOCEPTOR BLOCKERS



I hereby certify that this Information Disclosure Statement, Form PTO 1449 with refs.; Return Postcard
(Identify type of correspondence)

is being deposited with the United States Postal Service as first class mail in an envelope addressed to: The

Assistant Commissioner for Patents, Washington, D.C. 20231 on

March 2, 2001

(Date)

Kim A. Maurer

(Typed or Printed Name of Person Mailing Correspondence)

(Signature of Person Mailing Correspondence)

Note: Each paper must have its own certificate of mailing.

RECEIVED
MAR 30 2001
TECH CENTER 1600/2900